Company / PP&E (Net)
Jade Biosciences, Inc. PP&E (Net) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$6.0K
FY2024
5-year range
$6.0K / $288.0K
FY2020-FY2024
Trend
-97.9%
vs FY2023
Sector context
#197 of 197
Health Care
What the data says
Among 197 Health Care companies, Jade Biosciences, Inc. is in the bottom 0% for pp&e (net). Declined from $242,000 to $6,000 over the past 2 years.
Based on SEC 10-K filings.
$6,000 in FY2024 with a 3-year CAGR of -68.2%.
Declined from $242,000 to $6,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -68.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 197This company $6.0K Sector average $773.5M
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -68.2%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 97.9% year-over-year.
- Ranks #197 out of 197 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.0K | -97.9% |
| FY2023 | $288.0K | +19.0% |
| FY2022 | $242.0K | +30.1% |
| FY2021 | $186.0K | +376.9% |
| FY2020 | $39.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026